Literature DB >> 19128364

What are the keys to successful adrenal venous sampling (AVS) in patients with primary aldosteronism?

William F Young1, Anthony W Stanson.   

Abstract

Adrenal venous sampling (AVS) is the criterion standard to distinguish between unilateral and bilateral adrenal disease in patients with primary aldosteronism. The keys to successful AVS include appropriate patient selection, careful patient preparation, focused technical expertise, defined protocol, and accurate data interpretation. The use of AVS should be based on patient preferences, patient age, clinical comorbidities, and the clinical probability of finding an aldosterone-producing adenoma. AVS is optimally performed in the fasting state in the morning. AVS is an intricate procedure because the right adrenal vein is small and may be difficult to locate - the success rate depends on the proficiency of the angiographer. The key factors that determine the successful catheterization of both adrenal veins are experience, dedication and repetition. With experience, and focusing the expertise to 1 or 2 radiologists at a referral centre, the AVS success rate can be as high as 96%. A centre-specific, written protocol is mandatory. The protocol should be developed by an interested group of endocrinologists, radiologists and laboratory personnel. Safeguards should be in place to prevent mislabelling of the blood tubes in the radiology suite and to prevent sample mix-up in the laboratory.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19128364     DOI: 10.1111/j.1365-2265.2008.03450.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  45 in total

Review 1.  Diagnosis and treatment of primary aldosteronism.

Authors:  Paolo Mulatero; Silvia Monticone; Franco Veglio
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 2.  Diagnosis and surgical management for primary hyperaldosteronism.

Authors:  Ravi Munver; Jennifer Yates
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

3.  Laboratory investigation of primary aldosteronism.

Authors:  Michael Stowasser; Paul J Taylor; Eduardo Pimenta; Ashraf H Al-Asaly Ahmed; Richard D Gordon
Journal:  Clin Biochem Rev       Date:  2010-05

4.  A patient with concurrent primary aldosteronism and Page kidney.

Authors:  Chin-Chi Kuo; Huan-Lun Hsu; Chao-Yuan Huang; Kao-Lang Liu; Vin-Cent Wu; Ching-Wei Tsai; Wei-Jie Wang
Journal:  Endocrine       Date:  2010-06-24       Impact factor: 3.633

Review 5.  Primary aldosteronism and a Texas two-step.

Authors:  Richard J Auchus
Journal:  Rev Endocr Metab Disord       Date:  2011-03       Impact factor: 6.514

Review 6.  Issues in the Diagnosis and Treatment of Primary Aldosteronism.

Authors:  Jacopo Burrello; Silvia Monticone; Fabrizio Buffolo; Martina Tetti; Giuseppe Giraudo; Domenica Schiavone; Franco Veglio; Paolo Mulatero
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-04-09

7.  Adrenal venous sampling for stratifying patients for surgery of adrenal nodules detected using dynamic contrast enhanced CT.

Authors:  Jin Young Kim; See Hyung Kim; Hee Jung Lee; Young Hwan Kim; Mi Jeong Kim; Seung Hyun Cho
Journal:  Diagn Interv Radiol       Date:  2014 Jan-Feb       Impact factor: 2.630

Review 8.  Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.

Authors:  Laurence Amar; Pierre-François Plouin; Olivier Steichen
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123

9.  Adrenal venous sampling in primary aldosteronism: a low dilution of adrenal venous blood is crucial for a correct interpretation of the results.

Authors:  Jiri Ceral; Miroslav Solar; Antonin Krajina; Marek Ballon; Petr Suba; Jan Cap
Journal:  Eur J Endocrinol       Date:  2009-07-15       Impact factor: 6.664

10.  Adrenal venous sampling: where is the aldosterone disappearing to?

Authors:  Miroslav Solar; Jiri Ceral; Antonin Krajina; Marek Ballon; Eva Malirova; Milos Brodak; Jan Cap
Journal:  Cardiovasc Intervent Radiol       Date:  2009-10-01       Impact factor: 2.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.